HCC1569 Xenograft Model Service for Breast Cancer

The HCC1569 xenograft model represents a highly valuable and translationally potent in vivo platform specifically designated for targeting HER2-amplified breast cancers and overcoming therapeutic resistance. Alfa Cytology delivers a comprehensive, end-to-end HCC1569 xenograft model service, blending optimized inoculation strategies with profound preclinical expertise to accelerate your oncology drug development programs.

Overview of HCC1569 Xenograft Model for Breast Cancer

The HCC1569 cell line is a well-established human mammary carcinoma model characterized by the profound amplification and overexpression of the human epidermal growth factor receptor 2 (HER2/ERBB2) oncogene. Originally isolated from a primary ductal carcinoma, this model structurally represents the aggressive HER2-positive molecular subtype of breast cancer. Crucially, HCC1569 cells exhibit an intrinsic resistance to certain standard HER2-targeted therapies, such as trastuzumab, making this model an indispensable tool for researchers aiming to investigate secondary resistance pathways and validate next-generation therapeutics, including novel antibody-drug conjugates (ADCs), bispecific antibodies, and small-molecule tyrosine kinase inhibitors (TKIs).

When established in vivo via transplantation into immunocompromised mice, HCC1569 cells form solid tumors that faithfully preserve the histopathological architecture and genomic features of clinical HER2+ tumors. The model exhibits steady, reliable growth kinetics that facilitate a clear window for evaluating therapeutic interventions without the confounding variables of erratic tumor regression.

Fig 1. Cell killing of breast cancer lines using trispecific anti-Ly6E/B7-H4/CD3 antibodies. (Dicara DM, et al., 2022)

Cell Line Information: HCC1569

The HCC1569 cell line maintains a stable epithelial morphology and high HER2 expression levels throughout both in vitro cultivation and in vivo modeling phases.

Alfa Cytology is dedicated to providing robust, reproducible preclinical data through rigorous technical execution and scientific transparency. Our oncology team specializes in complex human tumor xenograft methodologies, ensuring that every HCC1569 study is underpinned by fully authenticated cell banks and uniform experimental conditions.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC1569 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2 expression and PK/PD profiling. Leveraging our expertise in HER2-positive breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC1569 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly monitored workflow to build and validate the HCC1569 xenograft model:

• Cell Culture & QC: HCC1569 cells are expanded under optimized in vitro growth conditions. Rigorous quality control checks, including STR profiling and mycoplasma screening, are mandatory to guarantee phenotypic identity and high cell viability before inoculation.
• Host Adaptation: Standardized immunocompromised mice (such as BALB/c Nude or SCID strains) are carefully selected and allowed to acclimate to our controlled laboratory facility to achieve baseline physiological stability.
• Standardized Inoculation: A highly viable, calibrated suspension of HCC1569 cells is prepared and often combined with a biological matrix carrier to enhance initial cell retention. The mixture is precisely injected in vivo into the subcutaneous flank or orthotopically into the mammary fat pad.
• Longitudinal Growth Monitoring: Following model establishment, tumor growth and animal weights are tracked systematically using high-precision digital calipers. This regular tracking ensures accurate growth curve formulation and maintains strict animal welfare criteria.
• Stratification & Grouping: When tumors reach a predefined, statistically optimal volume range, the mice are randomized into balanced treatment and control cohorts to ensure uniform baseline parameters prior to dosing.

Fig 2. HCC1569 Xenograft Model Construction Workflow

Case Study - HCC1569 Xenograft Model Development

In a recent preclinical project conducted at Alfa Cytology, the HCC1569 xenograft model was successfully utilized to evaluate the therapeutic efficacy of a novel small-molecule inhibitor designed to bypass trastuzumab resistance. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, facilitating an unobstructed assessment of drug mechanics. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group.

Why Choose Alfa Cytology?

Choosing the right partner for your HER2-positive breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• HER2 Subtype Specialization: Extensive track record in maintaining and establishing resistant HER2-amplified models.
• Technical Reproducibility: Refined injection techniques that yield consistent tumor growth kinetics and minimize intra-group variance.
• Comprehensive Endpoints: Full capabilities for downstream profiling, including IHC for HER2 expression, multiplex biomarker analysis, and PK/PD tissue processing.
• Scientific Integrity: Rigid adherence to international standards and transparent reporting through the entire study lifecycle.

Contact Us

Are you ready to accelerate your HER2+ breast cancer drug discovery program with the robust HCC1569 xenograft platform? The senior scientific team at Alfa Cytology is fully equipped to design and execute a tailored study protocol that directly answers your research questions. Please reach out to us today to speak directly with an oncology specialist, or contact us to receive a customized project consultation and detailed quotation.

For research use only. Not intended for any clinical use.